Home > Companies > United Family Healthcare

United Family Healthcare

ufh.com.cn

After 21 years of development, United Family Healthcare (UFH) now offers a complete range of medical services including sophisticated surgical and interventional solutions that match top hospitals around the world. A true pioneer in Asia’s healthcare development, we lead the way in international standards of service in high-end, private medical care. With 7 hospitals and 14 satellite clinics in Beijing, Shanghai, Guangzhou, Tianjin, Qingdao, Nanjing, Wuxi, Hangzhou and Bo'ao, UFH is recognized as one of the premium healthcare systems nationwide and is internationally accredited by the Joint Commission International (JCI). There are over 400 full-time doctors from 25 different countries and regions working in UFH. Additionally there are over 1100 part-time experts and over 900 nurses on the team.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Research

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

CANCER PREVENTION PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR CPP-1X/SUL FOR TREATMENT OF FAMILIAL ADENOMATOUS POLYPOSIS

Cancer Prevention Pharmaceuticals, CPP-1X/sul | June 29, 2020

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. The clinical...

Business Insights

ACURX PHARMACEUTICALS TO JOIN THE RUSSELL MICROCAP INDEX®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate gr...

Pharma Tech

GERRESHEIMER AND ZOLLNER ENTER INTO A STRATEGIC PARTNERSHIP FOR ELECTRONICALLY CONTROLLED MEDTECH SYSTEMS FROM A SINGLE SOURCE

Gerresheimer AG | August 18, 2022

Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership. Starting immediately, they will offer pharmaceutical, healthcare and biotech companies their conceptual design, development and manufacturing capacities for drug delivery and medical technology systems, including complete electronics, from one single source. Gerresheimer serves as the central point of contact for customers. The market-leading p...

Research